全球生命科學取向中間體企業：DowPharma

Abstract

A concise market analysis, including:

• Major U.S. and international trends with potentially significant impact on the life science intermediates industry during the next five years, including industry consolidation, market globalization, environmental regulations, etc.
• Analysis of major market segments.
• Review of key geographic regions, including North America, Europe, Asia, Latin America and others.
• Five-year worldwide market forecasts for:
  • Major market segments.
  • Key geographic regions.

Table of Contents

SECTION I. EXECUTIVE SUMMARY

• A 3-5 page synopsis of main sections.

SECTION II. BUSINESS ORGANIZATION

• History of the life science intermediates business evolution, important to the understanding of the corporate culture, management mentality and strategies.
• Recent acquisitions, divestitures and significant organizational changes.
• Current organizational structure.

SECTION III. SENIOR MANAGEMENT

• Background of key executives.

SECTION IV. FACILITIES AND EMPLOYEES

• Major administrative, manufacturing and R&D facilities in the U.S. and abroad.
• New plants under construction.
• U.S. and international work force size and distribution.

SECTION V.TECHNOLOGICAL KNOW-HOW

• Internally developed and acquired technologies, and related capabilities.
• Proprietary technologies and patent litigations.

SECTION VI. PRODUCT PORTFOLIO

• Extensive review of major product lines.

SECTION VII. MARKETING TACTICS

• Major promotional strategies.
• Distribution approaches.
• Product service and support.

SECTION VIII. FINANCIAL ANALYSIS

• Sales and operating profit by division, product line, geographic region and country.
• Five-year sales and profit performance.

SECTION IX. R&D EXPENDITURES AND MAJOR PROGRAMS

• Estimated R&D budget.
• Research facilities and staff.
• New technologies, products and applications in development.

SECTION X. COLLABORATIVE ARRANGEMENTS

• Major joint venture, distribution, OEM and licensing partners, both industrial and academic.
• Terms of collaborative agreements and specific products involved.

SECTION XI. STRATEGIC DIRECTION

• Specific business, new product development and marketing strategies.
• Strengths and weaknesses.
• Anticipated acquisitions, joint ventures and divestitures.